Atopic dermatitis (AD) is a common chronic allergic skin disease characterised by dry, scaly skin, inflammation, increased skin permeability, susceptibility to allergy causing sensitive reactions to normally innocuous elements and vulnerability to surface infection
[1],
[2]. The lifetime prevalence of AD is estimated to 15–30% in children and 2–10% in adults while the incidence of AD has increased by 2- to 3-fold during the past 3 decades in industrialised countries
[1], and thus AD has significant socioeconomic and personal impacts in these countries
[3]. Recently, skin barrier dysfunction has been recognised as one of the key factors in the development of AD
[2],
[4],
[5], although relatively little is understood about its underlying mechanisms due to its complexity.
The skin barrier is physically composed of the cornified layer, where keratin-filled and anucleated keratinocytes (corneocytes) are densely packed with skin lipids (). Skin barrier homeostasis is attained by balancing the differentiation of granular layer keratinocytes to corneocytes against elimination of corneocytes at the skin surface (desquamation)
[6]. The latter occurs as the result of cleavage of corneodesmosomes (), which bind corneocytes together, by serine proteases called kallikreins (KLKs)
[7]. Excessive activities of KLKs can impair the skin barrier via premature breakdown of corneodesmosomes by KLKs
[8] and increase corneocyte desquamation. Accumulating evidence indicates malfunctions in the spatial and temporal control of KLK activity in AD patients is one of the main causes for their defective skin barrier homeostasis
[9].
KLKs are synthesised as inactive precursors and are secreted into the extracellular space, where they are activated by another active KLK by irreversible proteolysis ()
[10]. The activity of each KLK is further regulated by direct interaction with proteinase inhibitors such as Lympho-epithelial Kazal-type related inhibitor (LEKTI)
[11], and by changes in pH
[12]. Indeed, compared to healthy control (HC), AD patients have the following three characteristics: (1) higher protein level of KLKs in stratum corneum
[13], (2) significant decrease in the expression of
SPINK5 encoding LEKTI
[14], and (3) higher pH level
[15],
[16], all of which result in higher KLK activity. In addition to KLKs and LEKTI, recent findings have suggested that protease-activated receptors type 2 (PAR2) plays a significant role in skin barrier homeostasis
[17]–
[19]. PAR2 is cleaved and activated by active KLKs, resulting in Ca

release and mitogen activated protein kinase (MAPK) activation. In physiological conditions (healthy status), PAR2 signalling is reported to regulate the differentiation of keratinocytes
[20], while in pathological conditions including AD, this signalling upregulates cytokine production by keratinocytes and induces immune response
[21].
The activities of KLKs and PAR2s are thus tightly regulated by a complex network of protein-protein interactions that remain, despite its pathological importance, poorly understood. Therefore, it is indispensable to reveal how different components such as KLK, LEKTI, PAR2 and pH affect the systems behaviour by their mutual interactions and feedback regulation, and to understand how these mechanisms are dysregulated at the system-level in AD patients. However, experimental data are currently limited and the entire regulatory mechanism is still obscure.
AD is a notoriously chronic disease: sensitive reactions including inflammation occur easily by external stimulus (eg. scratching) and may persist or even aggravate, even if the initiating stimulus no longer exists. These features, notably outbreak, persistence, and aggravation of inflammation, suggest the presence of a positive feedback loop
[22],
[23] in the regulatory system for KLK activity. Although such feedback loops have not been explicitly identified to date, feedback regulatory mechanisms of KLK activity are further suggested by the following experimental evidence: (1) cells within the inflammatory infiltrate produce KLKs as a product of the inflammatory response, in proportional level with the severity of a flare of AD
[7], (2) both KLKs
[13] and PAR2
[24] proteins are increased in AD lesions, (3) patients with different deficiency in
SPINK5 gene show different KLK expression level
[25], (4) the kinetics of skin barrier recovery is accelerated in PAR2 knockout than wild-type
[26], (5) keratinocytes have receptors for inflammatory cytokines such as IL1 and IL8 (downstream signals of PAR2 activation), thus can be activated in an autocrine manner
[27],
[28]. Importantly, KLK, LEKTI and PAR2 do not interact inside the cell, but are transported outside of the cell separately and only interact at the cell surface and in the extracellular space
[9].
Accordingly, we conduct a systems-level investigation of the feedback regulation of KLK activity in skin. To achieve the overall aim of better understanding underlying mechanisms of skin barrier dysfunction in AD patients, we carry out the investigation in three steps. First, we develop a novel mathematical model of the KLK activation system and provide a framework to coherently explain the current experimental knowledge on AD. The mathematical model we propose in this paper consists of four core mechanisms for KLK activation: (1) KLK self-activation, (2) KLK inhibition by LEKTI, (3) PAR2 activation by KLK, and (4) feedback regulation of KLK and LEKTI via activated PAR2. The first three mechanisms have been rather well characterised experimentally while the feedback mechanism has been implicitly suggested based on different experimental evidence as described above
[7],
[13],
[24]–
[26] and awaits the explicit identification by experiments. Second, using this mathematical framework, we investigate the fundamental and core mechanisms responsible for qualitatively different behaviours of the system to characterise HC and AD patients. We hypothesise models with different feedback loops and identify the plausible system behaviours by bifurcation analysis. The proposed models successfully reproduce the clinically well-known and essential AD features: persistent inflammation triggered by lower level of external stimulus for AD than for HC. To gain further insight, we perform sensitivity analysis
[29], motivating the detailed study of parameter-dependencies of system behaviours; furthermore, this analysis identifies the important balance between degradation rates and rates for feedback kinetics. Lastly, the model predictions are verified with experimental data. Since PAR2 activity is difficult to directly measure by conventional experiments including Western blotting of signalling proteins, we propose a novel way of evaluating PAR2 downstream signal activities using microarray analysis. Specifically, we apply principal component analysis (PCA) to microarray data of HC and AD samples and derive an indicator (PAR2 score) of the PAR2 downstream inflammation level that can capture the difference between HC and AD patients. The model predictions are then verified using the PAR2 score for HC and AD patients and confirm the coherency of the model. All the results presented here support the presence and significance of feedback loops in the regulation of KLK activity, and thus this work attempts to motivate a variety of future experiments for further study in order to better understand the fundamental regulatory mechanisms of skin barrier homeostasis in AD and healthy individuals.